Liver Cancer Trial, Recruiting NCT06689670 Sponsor: inTumo Therapeutics, Inc. Condition: Liver Cancer
Back to Liver Cancer

Liver Cancer Trial, Recruiting

NCT06689670
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with primary or secondary liver cancer (cancer that started in the liver, or cancer that has spread to the liver from elsewhere).
  • People whose overall health and activity level falls within a moderate range — specifically, an ECOG Performance Status score of 0 to 2 (confirm with trial site for what this means in your situation).
  • People who are 18 years of age or older and under 100 years of age.
  • People who are expected to live for at least 3 more months.
  • People whose liver cancer has been assessed as not suitable for surgery to remove the tumour or for a liver transplant.
  • People who are able to understand and sign a consent form explaining what the study involves.
  • People who are willing and able to follow all study requirements, including attending all procedures, medical check-ups, and follow-up visits.

Who may not be able to join:

  • People whose liver is not functioning well enough — specifically those with a Child-Pugh C classification, moderate to severe fluid build-up in the abdomen, blood clotting problems, or severe liver scarring (confirm with trial site).
  • People with certain blood test results showing the liver is under significant stress — specifically, liver enzyme levels (AST or ALT) more than 5 times the normal upper limit, or a bilirubin level above 2.0 mg/dL (confirm with trial site).
  • People who have a bleeding disorder.
  • People who have had an allergic reaction or serious intolerance to contrast dyes used in medical imaging scans.
  • People who have a serious, life-threatening illness or disease outside of the liver.
  • People with other health conditions — physical or mental — that the study doctor believes could prevent the treatment from working or could put the person at risk, such as an active infection, kidney problems, or significant ongoing illness.
  • People with a significant mental health condition.
  • Women who are pregnant, breastfeeding, or planning to become pregnant within the next 6 months.
  • People who are currently enrolled in another study involving a medical device, drug, or procedure that could affect the results of this trial.
  • People whose liver tumours do not show uptake of contrast dye on specific types of imaging scans (CT or MR angiography).
  • People whose liver tumours do not show a high level of blood supply when viewed on angiography imaging.
  • People who do not have CT or MRI scan results available at their screening visit, or who are unwilling or unable to have MRI scans during the study.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Fatih Selcukbiricik, MD, Koc University Hospital

Phone: +90 850-250-8250

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
inTumo Therapeutics, Inc.
Registry
ClinicalTrials.gov
Start date
28 October 2024
Est. completion
1 December 2027

Where this trial is recruiting

Turkey (Türkiye)

Primary endpoints

Ablation; Adverse events

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov